This site requires JavaScript and cookies to be enabled.

Which patients may be a good fit for Qelbree?

Explore patient profiles designed to help you identify patients who may be appropriate candidates for Qelbree. Download each profile to learn more about patient characteristics and treatment considerations for patients ages 6 years and older living with ADHD.

The profiles consist of fictional patients created for illustrative purposes and do not represent actual individuals. Treatment decisions should be individualized based on patient needs and clinical judgment.

Meet Leo

8 year-old boy living with ADHD

Hobbies: Soccer and video games

Diagnosis: Attention-deficit/hyperactivity disorder (ADHD) diagnosed at age 7 based on parent/teacher reports and clinical evaluation

Treatment History: Extended-release methylphenidate taken in the morning and immediate-release booster in the afternoon

Challenges:

  • Challenges with ADHD symptom control
  • Trouble during unstructured time
  • Caregiver concerns

Download full profile

Meet Elena

32 year-old new mother with ADHD

Job: Graphic designer and new mom

Diagnosis: ADHD diagnosed in her mid-20s prior to becoming a mother after long-standing challenges with organization, time management, and sustained attention

Treatment History: After discontinuing stimulant therapy during pregnancy, she is now exploring treatment options that align with her current situation as a breastfeeding mother

Challenges:

  • ADHD symptoms at both work and home
  • Treatment hesitation during breastfeeding

Download full profile

Meet Marcus

35 year-old professional with ADHD

Job: Software Engineer

Diagnosis: ADHD in early adulthood after long-standing difficulties with focus, follow-through, and organization

Treatment History: None currently for ADHD. Prior trials include amphetamine mixed salts (extended-release) and methylphenidate-based stimulant (extended-release)

Challenges:

  • Balancing the need for ADHD symptom control with a treatment option that fits his specific needs
  • Inconsistent symptom support
  • History of treatment interruptions

Download full profile

Meet Maya

17-year-old high school student with ADHD

Job: Full-time student

Diagnosis: ADHD diagnosed in early adolescence

Treatment History: Amphetamine mixed salts extended-release once daily in the morning

Challenges:

  • Challenging mornings
  • Struggles with follow-through and sitting still
  • Difficult evenings

Download full profile

Discover more:

Switching to Qelbree  Qelbree Dosing  Order Samples 
Pay as little as $20 for a 30 day or 90-day prescription

Commercially insured patients may pay as little as $20 for a 30-day or 90-day prescription.*

*Terms and conditions apply.

The Qelbree Savings Card can lower
out-of-pocket costs.

Qelbree offers a savings card to eligible patients. You can give your patients access to this savings card by emailing or printing the savings card.

Get a savings card 


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For additional information about the Qelbree Patient Savings and Support Program, call 1-866-398-0833.

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.